Pfizer settles last whistleblower suit for $14.5M; NJ offers $3.6M retraining for laid-off pharma workers;

> Pfizer ($PFE) agreed to pay $14.5 million to settle the last of 10 whistleblower lawsuits, wrapping up allegations that it marketed its Detrol drug for off-label use as a treatment for enlarged prostate and bladder obstruction. News

> The government of New Jersey said it would deliver $3.6 million in federal funding for retraining programs for laid-off pharma workers. Report

> Valeant Pharmaceuticals ($VRX) obtained $2 billion in new financing to refinance existing bridge loans and revolving debt. Item

> Bulgarian generics maker Sopharma plans to list its shares in Warsaw as well as on the Sofia bourse where they are now traded. Article

> Watson Pharmaceuticals ($WPI) won the FDA nod for a smaller-sized version of its testosterone patch Androderm. Story

> Janssen Therapeutics, a unit of Johnson & Johnson ($JNJ), got the FDA's blessing for a label update on its HIV drug Prezista to include positive data from a recent trial in treatment-naive patients. News

> Shanghai Modern Pharmaceutical plans to invest 277 million yuan ($43.4 million) to build a production base in Henan province. Article

> Actelion won its motion for a new trial in a licensing dispute with Asahi Kasei Pharma over the drug compound fasudil. Report

And Finally... Wal-Mart Stores won't offer health insurance to many part-time workers and will charge tobacco users more for their coverage. Story

Suggested Articles

With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections.

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.